Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]-SKI-249380 is a diagnostic radiopharmaceutical and a positron emission tomography (PET) tracer. It is a radiolabeled analog of the multi-targeted tyrosine kinase inhibitor dasatinib. This tracer is designed for imaging the in vivo pharmacokinetics of dasatinib and for detecting tumors in patients by visualizing the binding to dasatinib's molecular targets. It allows for non-invasive characterization of dasatinib pharmacokinetics in tumors and organs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]-SKI-249380.